JAMA Cardiology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
Chicago, IL
Joined August 2015
- Tweets15K
- Following348
- Followers50.3K
- Likes231
📊 Among adults with cardiovascular disease and overweight or obesity without diabetes, #Semaglutide showed cardiovascular benefit across levels of #Frailty, with no clear evidence that frailty reduced treatment efficacy. ja.ma/4BZnpba
101
Meta-analysis: In adults with and without #ChronicKidneyDisease, intensive blood pressure lowering reduced major cardiovascular events by 15% per 10-mm Hg lower systolic blood pressure. ja.ma/48OLpjC
Globally, #HeartFailure affected an estimated 56 million people in 2023, with increasing burden largely associated with population growth and aging. ja.ma/4zgMSu7
📈 #CoronaryInflammation measured from noncontrast cardiac computed tomography improved cardiovascular risk prediction beyond coronary artery calcium score and identified residual risk even among individuals with calcium scores of 0.
ja.ma/4zlUhs1
💬 Viewpoint: Aging populations are associated with a rising #CardiovascularDisease burden, supporting greater emphasis on prevention, early detection, and person-centered care that accounts for multimorbidity, frailty, and individual priorities.
ja.ma/4zknkML
ALT A JAMA Viewpoint article titled \"Beyond Screening\u2014Building a Maternal Mental Health Care System\" by Sugy Choi, PhD, Jonathan Cantor, PhD, Elizabeth Fitelson, MD, and Catherine Monk, PhD. Published online November 11, 2026.
1
778
🫀 Among patients with #Type2Diabetes and high cardiovascular risk, oral semaglutide reduced first and subsequent major cardiovascular events vs placebo, indicating a lower total burden of #CardiovascularDisease.
ja.ma/3WDzXER
ALT JAMA Cardiology infographic summarizing an RCT on oral semaglutide in high-risk type 2 diabetes. Findings show oral semaglutide significantly reduced 3-P MACE compared to placebo (First event HR 0.85; Total events MR 0.86).
From @JAMA_current: Among veterans with stable #CoronaryArteryDisease, upfront #PercutaneousCoronaryIntervention plus optimal medical therapy did not reduce long-term death or myocardial infarction vs optimal medical therapy alone.
ja.ma/4ivcpKV
#ScientificSessions26
💬 Editorial from @JAMA_current: In patients with stable #CoronaryArteryDisease and at least moderate inducible ischemia, long-term follow-up from #ISCHEMIA supports a medical therapy–first approach for most patients.
ja.ma/4BQk3XI
#ScientificSessions26
1
3
596
📊 Research Summary from @JAMA_current: Long-term follow-up in #ISCHEMIA-EXTEND indicates no significant all-cause mortality difference between initial invasive and conservative management of stable #CoronaryDisease.
ja.ma/4C05aCv
#ScientificSessions26
2
637
From @JAMA_current: Among patients with stable #CoronaryDisease and moderate or severe ischemia, an initial invasive strategy did not improve long-term survival vs an initial conservative strategy.
ja.ma/4iHE7TE
#ScientificSessions26
1
2
531
#AI analysis of clinical notes identified infrequent low-density lipoprotein cholesterol target documentation and heterogeneous reasons for nonescalation of #LipidLoweringTherapy in secondary prevention.
ja.ma/3WBA0B1
#ScientificSessions26
3
675
💬 Editorial from @JAMA_current: An individualized treatment approach for #ObstructiveSleepApnea may combine weight-reducing therapy with positive airway pressure, oral appliances, or other airway-directed treatments.
ja.ma/3UsM72N
#ScientificSessions26
📊 Research Summary from @JAMA_current: In 2 trials of adults with moderate to severe #ObstructiveSleepApnea and excess weight, oral orforglipron improved sleep-disordered breathing, body weight, and hypoxic burden.
ja.ma/4Am82Ie
#ScientificSessions26
1
479
#ScientificSessions26 from @JAMA_current: Oral #Orforglipron improved apnea-hypopnea index, hypoxic burden, and body weight vs placebo in adults with #ObstructiveSleepApnea and obesity or overweight, w/ gastrointestinal adverse events reported more often.
ja.ma/4sStQsm
1
521
Thinking about submitting your #AHA26 research to @JAMA_current, @JAMACardio, or one of our other Network journals?
🎥 This video tells you what to expect from the submission and review process.
ja.ma/4kbBCeL
1
821
🎉 Final day of exhibits at #AHA26.
Find us at booth 537 to get recent articles for your trip home and ask about submitting your research presented at the meeting to @JAMA_current, @JAMACardio or one of our other JAMA Network journals.
ja.ma/4isj5cR
2
434
#ScientificSessions26 from @JAMA_current: Long-term follow-up in #ISCHEMIA-EXTEND indicates no significant all-cause mortality difference between initial invasive and conservative management of stable #CoronaryDisease.
ja.ma/3Wuz0ib
📊 Research Summary: Among patients with stable #CoronaryDisease and moderate or severe ischemia, an initial invasive strategy did not improve long-term survival vs an initial conservative strategy.
ja.ma/3WtOP8M
#ScientificSessions26
📣 Stay connected with the JAMA Network at #ScientificSessions26!
Explore the latest cardiovascular research, featured articles, editor sessions, and attendee resources from the JAMA Network: ja.ma/4erlOAO
1
333
✨Meet @JAMACardio Editor @HeartBobH Robert Harrington at #AHA26.
He will be at booth 537 in the exhibit hall today, Sunday, Nov 8 at 9:15-9:45 AM to answer questions and discuss your research and publishing opportunities with the JAMA Network.
